This inventor holds 1 USPTO granted patent. Top assignee: Scripps Korea Antibody Institute. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: **Innovative Contributions of Min Kyoung Ki in Cancer Research**
Introduction
Min Kyoung Ki is a noteworthy inventor based in Seoul, South Korea, recognized for his significant contributions to the field of cancer research. With a focus on antibody development, he has made strides that have the potential to impact therapeutic approaches in oncology.
Latest Patents
Min Kyoung Ki holds a patent for an "Antibody specific for CLEC14A and uses thereof." This innovative work encompasses a variety of applications, including:
- An antibody specifically binding to the CTLD (C-type lectin-like domain) of CLEC14A.
- Methods for preparing the antibody.
- Compositions aimed at suppressing angiogenesis, which involve the administration of this antibody.
- Approaches for diagnosing and treating cancer using the same antibody, along with related compositions and kits.
This patent represents a comprehensive exploration of developing therapeutic and diagnostic tools centered around the CLEC14A, demonstrating a solid commitment to addressing cancer treatment and angiogenesis.
Career Highlights
Min Kyoung Ki is affiliated with the Scripps Korea Antibody Institute, where he utilizes his expertise in antibody engineering and cancer biology. His work is pivotal in advancing the understanding of cancer mechanisms, particularly through the lens of angiogenesis suppression.
Collaborations
Throughout his career, Min has collaborated with esteemed colleagues like Suk Mook Lee and Mee Hyun Jeoung. These collaborations are instrumental in expanding research efforts, enhancing the potential for innovative discoveries and applications in cancer therapeutics.
Conclusion
Min Kyoung Ki's contributions to the field of cancer research through his unique patent illustrate the power of innovation in addressing critical health challenges. His ongoing work at the Scripps Korea Antibody Institute, combined with effective collaborations, positions him as a key figure in the pursuit of new treatment modalities for cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile